Please assess the completion status of the following clinical trial:

Trial Title: Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histochemical diagnosis of AL amyloidosis based on detection of green birefringent material in Congo red-stained tissue specimens by polarizing microscopy~* Measurable disease, as defined by one of the following:~  * Serum monoclonal protein ≥ 1.0 g by serum electrophoresis~ * Urine monoclonal protein \> 200 mg by 24-hour urine electrophoresis~ * Serum immunoglobulin free light chain ≥ 10 mg/dL AND abnormal serum immunoglobulin kappa to lambda free light chain ratio~* Symptomatic organ involvement with amyloid to justify therapy~  * May include liver involvement, cardiac involvement, renal involvement, grade 1 peripheral neuropathy, or soft tissue involvement~ * Must have more than skin purpura or carpal tunnel syndrome~* No amyloid-specific syndrome, such as carpal tunnel syndrome or skin purpura, as only evidence of disease~  - Vascular amyloid only in a bone marrow biopsy specimen or in a plasmacytoma is not indicative of systemic amyloidosis~* No clinically overt multiple myeloma (i.e., monoclonal BMPC \> 30%, bone lesions, or hypercalcemia)~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* ANC ≥ 1,000/μL~* Platelet count ≥ 75,000/μL~* Creatinine \< 3.0 mg/dL~* Not pregnant~* Negative pregnancy test~* Fertile patients must use two acceptable methods of contraception for ≥ 28 days prior to, during, and for ≥ 28 days after completion of study treatment~* No nursing during and for ≥ 28 days after completion of study treatment~* No blood, semen, or sperm donation during and for ≥ 28 days after completion of study treatment~* No malignancies within the past 5 years except treated basal cell or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast~* No neuropathy ≥ grade 2, defined as motor neuropathy (symptomatic weakness interfering with function, but not interfering with activities of daily living \[ADL\]) or sensory neuropathy (sensory alteration or paresthesia \[including tingling\], interfering with function, but not interfering with ADL)~* No uncontrolled infection~* No syncope within the past 30 days~* No known hypersensitivity to thalidomide, including desquamating rash with thalidomide in the past~* No known seropositivity for HIV~* No active hepatitis A, B, or C~* No New York Heart Association class III or IV heart disease~* No venous thromboembolic event within the past 42 days~* Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation - Patients intolerant to aspirin may use low molecular weight heparin~PRIOR CONCURRENT THERAPY:~* No prior lenalidomide~* More than 2 weeks since prior and no other concurrent anticancer agents or treatments~* More than 4 weeks since prior experimental agents~* No other concurrent corticosteroids except chronic steroids (maximum dose 20 mg/day of prednisone equivalent) for disorders other than amyloidosis (e.g., adrenal insufficiency or rheumatoid arthritis)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CRD (Type: EXPERIMENTAL): Lenalidomide 15mg daily (days 1-21)~Cyclophosphamide 300 mg/m\^2 (days 1, 8, 15)~Dexamethasone 40 mg weekly

Based on this trial design, predict the completion outcome and termination type (if applicable).